Valeant Settles for Second Best with US$14.5 B Salix Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 3 (Table of Contents)
Published: 12 Mar-2015
DOI: 10.3833/pdr.v2015.i3.2097 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In its biggest deal to date, Valeant Pharmaceuticals International has agreed to buy gastrointestinal specialist Salix Pharmaceuticals for an enterprise value of approximately US$14...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018